RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:488627

Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome

low confidenceDisorder

Publications

558

Trials

0

Interventional, condition-specific

Researchers

49

Distinct authors in sample

Gene link

PUS3

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare multiple anomalies/ syndrome with characterized by onset of global , severe , growth deficiency, microcephaly, strabismus, blue-gray sclerae, and extensive Mongolian spots. Some patients also present with . Brain imaging may demonstrate variable abnormalities including cerebral atrophy, thin corpus callosum, ventriculomegaly, or arachnoid cysts.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

MRT55 · intellectual disability, autosomal recessive 55 · intellectual disability, autosomal recessive type 55 · mental retardation, autosomal recessive 55 · mental retardation, autosomal recessive type 55 · neurodevelopmental disorder with microcephaly and gray sclerae · neurodevelopmental disorder with microcephaly and grey sclerae

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — PUS3

  2. LiteraturePresent

    558 matched papers (398 in last 10 years) Source

  3. Phenotype characterisedPresent

    53 HPO annotations (e.g. Coarse facial features; Severe intellectual disability; Reduced social responsiveness) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (PUS3).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

53

Associated phenotypes · MONDO:0014886

  • Coarse facial features
  • Severe intellectual disability
  • Reduced social responsiveness
  • Arachnoid cyst
  • Microcephaly

Showing 5 of 53 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

558

558 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

558 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

398 in the last 10 years · low confidence

Phrase hits: 7 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

49

Distinct author names in 7 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Reis A2 papers · 2018

    Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.

    Papers in Europe PMC
  2. 02
    Riazuddin S2 papers · 2018

    National Centre of Excellence in Molecular Biology, University of The Punjab, Lahore 53700, Pakistan; Center for Genetic Diseases, Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan Institute of Medical Sciences, Islamabad 44000, Pakistan; Allama Iqbal Medical College, University of Health Sciences, Lahore 54600, Pakistan.

    Papers in Europe PMC
  3. 03
    Abou Jamra R1 paper · 2018

    Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; Institute of Human Genetics, University Medical Center Leipzig, 04109 Leipzig, Germany.

    Papers in Europe PMC
  4. 04
    Ahmed ZM1 paper · 2018

    Department of Otorhinolaryngology-Head and Neck Surgery, University of Maryland, School of Medicine, Baltimore, MD 21201-1734, USA.

    Papers in Europe PMC
  5. 05
    Borrell A1 paper · 2021

    BCNatal, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Catalonia, Spain.

    Papers in Europe PMC
  6. 06
    Bove J1 paper · 2025

    Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts, USA.

    Papers in Europe PMC
  7. 07
    Coller JM1 paper · 2019

    Department of Genetics and Genome Sciences and Center for RNA Science and Therapeutics, Case Western Reserve University, Cleveland, Ohio 44106, USA; email: ashleigh.schaffer@case.edu.

    Papers in Europe PMC
  8. 08
    de Boer L1 paper · 2018

    Department of Paediatrics, Radboud Center for Mitochondrial Medicine, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.

    Papers in Europe PMC
  9. 09
    de Brouwer APM1 paper · 2018

    Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6500HB Nijmegen, the Netherlands. Electronic address: arjan.debrouwer@radboudumc.nl.

    Papers in Europe PMC
  10. 10
    Dinges N1 paper · 2018

    Laboratory of RNA Epigenetics, Institute of Molecular Biology (IMB), 55128 Mainz, Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (3)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome" OR "MRT55" OR "intellectual disability, autosomal recessive 55" OR "intellectual disability, autosomal recessive type 55" OR "mental retardation, autosomal recessive 55" OR "mental retardation, autosomal recessive type 55" OR "neurodevelopmental disorder with microcephaly and gray sclerae" OR "neurodevelopmental disorder with microcephaly and grey sclerae") OR ("PUS3" OR "PUS3 syndrome" OR "PUS3-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Severe growth deficiency-strabismus-extensive dermal melanocytosis-intellectual disability syndrome" OR "MRT55" OR "intellectual disability, autosomal recessive 55" OR "intellectual disability, autosomal recessive type 55" OR "mental retardation, autosomal recessive 55" OR "mental retardation, autosomal recessive type 55" OR "neurodevelopmental disorder with microcephaly and gray sclerae" OR "neurodevelopmental disorder with microcephaly and grey sclerae"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (558) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T17:26:32.339Z